We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
Read MoreHide Full Article
Key Takeaways
AstraZeneca's anselamimab missed the primary endpoint in both phase III CARES studies for AL amyloidosis.
The drug showed a clinically meaningful benefit in a prespecified subgroup, but details remain undisclosed.
AZN plans a full analysis of the data and will present findings at an upcoming medical meeting.
AstraZeneca (AZN - Free Report) reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called light chain (AL) amyloidosis.
Both studies — part of the phase III CARES clinical program — were designed to assess anselamimab plus standard of care against placebo in patients with stage IIIa and stage IIIb AL amyloidosis, respectively. The primary endpoint of both studies was the same — a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVH). In other words, the studies were designed to determine whether the drug could help patients live longer and reduce heart-related hospitalizations.
Treatment with anselamimab failed to achieve statistical significance for the primary endpoint in either of the two studies. Though AstraZeneca mentioned that the drug showed clinically meaningful improvement in a prespecified patient subgroup, it did not disclose details of the same. Based on these findings, the company noted that anselamimab is the first fibril depleter to show potential benefit in AL amyloidosis. AZN is currently conducting a full analysis of the results and plans to share the findings at a future medical meeting.
AL amyloidosis is caused by deposits of amyloid protein in the body due to defective plasma cells. If left untreated, these deposits can cause progressive organ damage and may even lead to premature death, most commonly due to cardiac failure. Per AstraZeneca, around 74,000 people across the world are living with this disease.
AZN Stock Performance
Year to date, AstraZeneca’s shares have gained 7% against the industry’s 1% decline.
Image Source: Zacks Investment Research
Another Setback in the AL Amyloidosis Space
AstraZeneca is not the first to report a setback in this space. In May, Prothena (PRTA - Free Report) announced a similar setback with its own AL amyloidosis drug, birtamimab, in the phase III AFFIRM-AL study.
The AFFIRM-AL study failed to achieve its primary endpoint of time to ACM. Treatment with the Prothena drug also failed to meet any of its secondary endpoints. Based on this setback, PRTA ended the development of birtamimab and announced a restructuring program last month to curb cash burns, including a 63% workforce reduction.
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold).
In the past 90 days, loss per share estimates for Akero’s 2025 have improved from $4.08 to $3.96. Loss per share estimates for 2026 have narrowed from $4.35 to $4.27 during the same period. AKRO stock has surged 93% year to date.
Akero’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 48.90%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared over 130% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
Key Takeaways
AstraZeneca (AZN - Free Report) reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called light chain (AL) amyloidosis.
Both studies — part of the phase III CARES clinical program — were designed to assess anselamimab plus standard of care against placebo in patients with stage IIIa and stage IIIb AL amyloidosis, respectively. The primary endpoint of both studies was the same — a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVH). In other words, the studies were designed to determine whether the drug could help patients live longer and reduce heart-related hospitalizations.
Treatment with anselamimab failed to achieve statistical significance for the primary endpoint in either of the two studies. Though AstraZeneca mentioned that the drug showed clinically meaningful improvement in a prespecified patient subgroup, it did not disclose details of the same. Based on these findings, the company noted that anselamimab is the first fibril depleter to show potential benefit in AL amyloidosis. AZN is currently conducting a full analysis of the results and plans to share the findings at a future medical meeting.
AL amyloidosis is caused by deposits of amyloid protein in the body due to defective plasma cells. If left untreated, these deposits can cause progressive organ damage and may even lead to premature death, most commonly due to cardiac failure. Per AstraZeneca, around 74,000 people across the world are living with this disease.
AZN Stock Performance
Year to date, AstraZeneca’s shares have gained 7% against the industry’s 1% decline.
Image Source: Zacks Investment Research
Another Setback in the AL Amyloidosis Space
AstraZeneca is not the first to report a setback in this space. In May, Prothena (PRTA - Free Report) announced a similar setback with its own AL amyloidosis drug, birtamimab, in the phase III AFFIRM-AL study.
The AFFIRM-AL study failed to achieve its primary endpoint of time to ACM. Treatment with the Prothena drug also failed to meet any of its secondary endpoints. Based on this setback, PRTA ended the development of birtamimab and announced a restructuring program last month to curb cash burns, including a 63% workforce reduction.
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold).
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Akero Therapeutics (AKRO - Free Report) and Agenus (AGEN - Free Report) . While AKRO sports a Zacks Rank #1 (Strong Buy) at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Akero’s 2025 have improved from $4.08 to $3.96. Loss per share estimates for 2026 have narrowed from $4.35 to $4.27 during the same period. AKRO stock has surged 93% year to date.
Akero’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 48.90%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared over 130% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.